Literature DB >> 14748875

Surveillance for newly acquired hepatitis C in Australia.

Monica C Robotin1, Joy Copland, Graham Tallis, David Coleman, Carolien Giele, Louise Carter, Jenean Spencer, John M Kaldor, Gregory J Dore.   

Abstract

BACKGROUND: The purpose of the present paper was to determine recent patterns of hepatitis C virus (HCV) transmission in Australia through a national system of enhanced surveillance of newly acquired hepatitis C.
METHODS: Demographic, clinical, and risk behavior information on newly acquired hepatitis C cases from 1997 to 2000 was collected. Newly acquired hepatitis C included cases of HCV antibody sero-conversion within a 12 month period and acute clinical hepatitis C cases.
RESULTS: Nine hundred and twelve cases of newly acquired hepatitis C were identified, representing 2.8% of all HCV notifications for this period. The majority of cases (72%) were diagnosed in people aged between 20 and 39 years. Injecting drug use was reported in the vast majority of cases (93%), with sexual transmission (2%) and tattooing (2%) reported in small numbers. HCV antibody sero-conversion was the mode of diagnosis in most cases (78%).
CONCLUSIONS: Injecting drug use is the main route of HCV transmission in Australia. As only a small proportion of HCV infections are detected as newly acquired, enhanced surveillance procedures, including increased regular HCV testing of at-risk populations are required to more effectively monitor recent patterns of transmission. Copyright 2004 Blackwell Publishing Asia Pty Ltd

Entities:  

Mesh:

Year:  2004        PMID: 14748875     DOI: 10.1111/j.1440-1746.2003.03270.x

Source DB:  PubMed          Journal:  J Gastroenterol Hepatol        ISSN: 0815-9319            Impact factor:   4.029


  11 in total

Review 1.  Treatment of acute HCV infection.

Authors:  Jason Grebely; Gail V Matthews; Gregory J Dore
Journal:  Nat Rev Gastroenterol Hepatol       Date:  2011-03-22       Impact factor: 46.802

2.  Patterns and characteristics of hepatitis C transmission clusters among HIV-positive and HIV-negative individuals in the Australian trial in acute hepatitis C.

Authors:  G V Matthews; S T Pham; M Hellard; J Grebely; L Zhang; A Oon; P Marks; I van Beek; W Rawlinson; J M Kaldor; A Lloyd; G J Dore; P A White
Journal:  Clin Infect Dis       Date:  2011-01-31       Impact factor: 9.079

3.  Epidemiological characteristics and medical follow-up of 61 patients with acute hepatitis C identified through the hepatitis C surveillance system in France.

Authors:  C Brouard; P Pradat; E Delarocque-Astagneau; C Silvain
Journal:  Epidemiol Infect       Date:  2007-08-16       Impact factor: 2.451

Review 4.  Needle syringe programmes and opioid substitution therapy for preventing hepatitis C transmission in people who inject drugs.

Authors:  Lucy Platt; Silvia Minozzi; Jennifer Reed; Peter Vickerman; Holly Hagan; Clare French; Ashly Jordan; Louisa Degenhardt; Vivian Hope; Sharon Hutchinson; Lisa Maher; Norah Palmateer; Avril Taylor; Julie Bruneau; Matthew Hickman
Journal:  Cochrane Database Syst Rev       Date:  2017-09-18

5.  Prevalence of hepatitis C infection in a population of asymptomatic people in a checkup unit in Mexico city.

Authors:  Nahum Méndez-Sánchez; Guadalupe Ponciano-Rodriguez; Norberto C Chávez-Tapia; Daniel Motola-Kuba; Paloma Almeda-Valdes; Karla Sánchez-Lara; Martha H Ramos; Misael Uribe
Journal:  Dig Dis Sci       Date:  2005-04       Impact factor: 3.199

Review 6.  Current and emerging antiviral treatments for hepatitis C infection.

Authors:  Joseph S Doyle; Esther Aspinall; Danny Liew; Alexander J Thompson; Margaret E Hellard
Journal:  Br J Clin Pharmacol       Date:  2013-04       Impact factor: 4.335

Review 7.  Epidemiology of hepatitis C virus infection.

Authors:  Miriam J Alter
Journal:  World J Gastroenterol       Date:  2007-05-07       Impact factor: 5.742

8.  Characteristics and treatment outcomes among HIV-infected individuals in the Australian Trial in Acute Hepatitis C.

Authors:  G V Matthews; M Hellard; P Haber; B Yeung; P Marks; D Baker; G McCaughan; J Sasadeusz; P White; W Rawlinson; A Lloyd; J Kaldor; G J Dore
Journal:  Clin Infect Dis       Date:  2009-03-01       Impact factor: 9.079

9.  Incidence analyses and space-time cluster detection of hepatitis C in Fujian Province of China from 2006 to 2010.

Authors:  Shunquan Wu; Fuquan Wu; Rongtao Hong; Jia He
Journal:  PLoS One       Date:  2012-07-19       Impact factor: 3.240

10.  The acceptability and feasibility of peer worker support role in community based HCV treatment for injecting drug users.

Authors:  Josephine Norman; Nick M Walsh; Janette Mugavin; Mark A Stoové; Jenny Kelsall; Kirk Austin; Nick Lintzeris
Journal:  Harm Reduct J       Date:  2008-02-25
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.